Clinical Trial Update: ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Brentuximab Vedotin + CHP versus standard CHOP in CD30-positive mature T-cell lymphomas completed; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Large Cell Lymphoma
• Non-hodgkin Lymphoma
• T-cell Lymphoma

Drugs mentioned

• Brentuximab vedotin (Brentuximab vedotin)

Snippet

Sponsor: Seagen Inc. | Conditions: Anaplastic Large-Cell Lymphoma, Non-Hodgkin Lymphoma | Phase 3 | Status: COMPLETED | Results posted: 2019-07-30